The company has initiated a large-scale clinical study to validate a non-invasive cervical cancer screening method.
Live Poll
Would you prefer using home-collected samples for medical screenings over visiting a clinic?
October 11, 2026
Murine Model Reveals CNS Lymphoma Immune SuppressionResearchers developed a new lymphoma model to explain the aggressive nature of primary central nervous system tumors.
October 11, 2026
Research Identifies AP2M1 Gene as TNBC DriverA new study reveals that the AP2M1 gene promotes tumor growth in triple-negative breast cancer by stabilizing EGFR.
October 10, 2026
Researchers Identified PTK7 Role in Cancer Immune EvasionNew findings reveal how the PTK7 protein helps triple-negative breast cancer cells repair DNA damage and evade the immune system.
October 10, 2026
Myofascial Release Improved Breast Cancer RecoveryA clinical trial found that targeted therapy enhanced shoulder mobility and strength in breast cancer patients.
October 10, 2026
Ojemda Induced Tumor Responses in Adult PatientsA study revealed that the oral targeted therapy shrank tumors in 43% of adult patients with specific rare RAF gene mutations.
October 10, 2026
Pola-R-GemOx Regimen Extended Survival for Lymphoma PatientsThe POLARGO clinical trial found that a new treatment approach significantly improved outcomes for those with relapsed lymphoma.
October 10, 2026
Rinatabart Sesutecan Shrank Ovarian Cancer TumorsA Phase 2 clinical trial showed the investigational drug induced tumor shrinkage in nearly half of treated patients.
October 9, 2026
Myopathy Patients Faced Higher Digestive Cancer RisksA 2026 meta-analysis linked idiopathic inflammatory myopathies to significantly increased rates of gastrointestinal cancers.
October 9, 2026
Researchers Identified Propionyl-CoA Signaling in Prostate CancerA newly discovered metabolic pathway may explain how prostate cancer cells drive tumor aggressiveness.
October 9, 2026
Researchers Targeted Tumor Microenvironments with AntibodyA new study has shown that the bispecific antibody OMTX305 can successfully destroy tumor-protecting fibroblasts.
